Suppr超能文献

高密度胰腺导管腺癌:临床特征与蛋白质组学全景

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape.

作者信息

Xu He, Hua Jie, Meng Qingcai, Wang Xiaohong, Xu Jin, Wang Wei, Zhang Bo, Liu Jiang, Liang Chen, Yu Xianjun, Shi Si

机构信息

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

Front Oncol. 2021 Feb 25;11:640820. doi: 10.3389/fonc.2021.640820. eCollection 2021.

Abstract

PURPOSE

Hypodensity of pancreatic ductal adenocarcinoma (PDAC) during contrast-enhanced computed tomography (CECT) examination is common, but a minority of PDAC patients exhibit hyperdense images. The present study examined the clinical characteristics and protein landscape of PDAC with hyperdensity.

MATERIALS AND METHODS

A total of 844 pathologically confirmed PDAC patients who underwent CECT before surgery were included. During the parenchymal phase of CECT, patients were assigned to the hyperdense or hypodense group based on CT values. Clinical and CT characteristics for predicting relapse-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox proportional hazards model. The expression of the tumor angiogenesis marker CD31 and stroma-related protein CTHRC1 were analyzed using immunohistochemistry (IHC) assay to evaluate differences between the two groups. Proteomics was performed to compare the possible mechanisms underlying the differential enhancement on CT scans.

RESULTS

Based on CECT, 43 and 801 PDAC patients had hyperdense and hypodense lesions, respectively. All 43 patients presented a hyperdense lesion in the parenchymal phase. The mean CECT values of the hyperdense group were higher than the hypodense group (102.5 ± 17.4 and 53.7 ± 18.7, respectively, 0.001). The hyperdense group had a better prognosis than the hypodense group (median RFS, 19.97 vs. 12.34 months, = 0.0176; median OS, 33.6 vs. 20.3 months, = 0.047). Multivariate analysis showed that age, higher CA19-9 levels (> 300 U/ml), tumor stage, tumor differentiation, tumor CT density, and adjuvant chemotherapy were significant independent prognostic factors for OS. CD31 immunohistochemical staining showed that the hyperdense PDACs had a higher microvessel density than the hypodense group ( 0.001). CTHRC1 expression was higher in the hypodense group ( = 0.019). Sixty-eight differentially expressed proteins were found using the tandem mass tag labeling-based quantification of the proteomes of PDAC tissue samples, and 7 proteins (POFUT1, PKP2, P0DOX4, ITPR1, HBG2, IGLC3, SAA2) were related to angiogenesis.

CONCLUSION

Patients who presented with a hyperdense mass on CECT had a higher microvessel density and better prognosis. Anti-angiogenic therapy may be suitable for these patients.

摘要

目的

在对比增强计算机断层扫描(CECT)检查中,胰腺导管腺癌(PDAC)表现为低密度较为常见,但少数PDAC患者表现为高密度影像。本研究探讨了高密度型PDAC的临床特征和蛋白质图谱。

材料与方法

纳入844例术前接受CECT检查且经病理确诊的PDAC患者。在CECT实质期,根据CT值将患者分为高密度组和低密度组。采用Kaplan-Meier法和Cox比例风险模型分析预测无复发生存期(RFS)和总生存期(OS)的临床及CT特征。采用免疫组织化学(IHC)检测分析肿瘤血管生成标志物CD31和基质相关蛋白CTHRC1的表达,以评估两组之间的差异。进行蛋白质组学分析以比较CT扫描差异强化背后的潜在机制。

结果

基于CECT,分别有43例和801例PDAC患者有高密度和低密度病变。所有43例患者在实质期均表现为高密度病变。高密度组的平均CECT值高于低密度组(分别为102.5±17.4和53.7±18.7,P<0.001)。高密度组的预后优于低密度组(中位RFS,19.97个月对12.34个月,P = 0.0176;中位OS,33.6个月对20.3个月,P = 0.047)。多因素分析显示,年龄、较高的CA19-9水平(>300 U/ml)、肿瘤分期、肿瘤分化程度、肿瘤CT密度和辅助化疗是OS的显著独立预后因素。CD31免疫组化染色显示,高密度型PDAC的微血管密度高于低密度组(P<0.001)。CTHRC1表达在低密度组更高(P = 0.019)。通过基于串联质量标签标记的PDAC组织样本蛋白质组定量分析,发现68种差异表达蛋白,其中7种蛋白(POFUT1、PKP2、P0DOX4、ITPR1、HBG2、IGLC3、SAA2)与血管生成有关。

结论

CECT上表现为高密度肿块的患者微血管密度更高,预后更好。抗血管生成治疗可能适用于这些患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/113c/7947874/646713ae3507/fonc-11-640820-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验